维奈克拉联合阿扎胞苷及高三尖杉酯碱治疗复发/难治急性髓系白血病的疗效及机制
Efficacy and mechanism of venetoclax combined with azacitidine and homoharringtonine in treatment of relapsed/refractory acute myeloid leukemia
程森 1杨海平 1赵小强 1黄晖婷 1辛静怡1
作者信息
- 1. 河南科技大学临床医学院,河南洛阳 471000
- 折叠
摘要
传统化疗方案治疗急性髓系白血病(AML)有一定疗效,但是复发/难治AML的治疗往往缓解率低、耐药性高、治疗效果欠佳,鉴于目前复发/难治AML的诊治现状,需要高效、耐受良好的治疗方案来改善患者的预后,以为AML的治疗提供新选择.本文针对维奈克拉联合阿扎胞苷及高三尖杉酯碱治疗复发/难治AML的疗效及机制做一综述.
Abstract
Traditional chemotherapy regimens have certain efficacy in the treatment of acute myeloid leukemia(AML),but the treatment of relapsed/refractory AML often results in low response rates,high resistance,and suboptimal therapeutic outcomes.Based on the current state of diagnosis and treatment for relapsed/refractory AML,there is a need for highly efficient and well-tolerated treatment regimens to improve the prognosis of AML patients and provide new choices for AML therapy.This article overviews the efficacy and mechanism of venetoclax in combination with azacitidine and homoharringtonine in the treatment of relapsed/refractory AML.
关键词
急性髓系白血病,复发,难治/维奈克拉/高三尖杉酯碱/阿扎胞苷Key words
Acute myeloid leukemia,relapsed,refractory/Venetoclax/Homoharringtonine/Azacitidine引用本文复制引用
基金项目
河南省医学科技攻关计划(联合共建)项目(LHJG20190547)
出版年
2024
NETL
NSTL
万方数据